Skip to main content

Advertisement

Table 1 Demographic and tumor-related characteristics of the study population: age, race, AJCC pathologic stage, hormone receptor status, and time from completion of trastuzumab (when applicable)

From: Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

Characteristic Treatment-naïve HER2pos IBC (n = 22) HER2pos IBC treated with T + C (n = 65)
   Neoadjuvant (n = 40) Adjuvant (n = 25)
Age, years, mean ± standard error 56.8 ± 3.1 45.9 ± 2.1 57.2 ± 2.6
Age, years, range 36–88 24–81 28–85
Race/ethnicity, number (%)    
 Caucasian 17 (77.3) 35 (87.5) 19 (76.0)
 African-American 2 (9.1) 3 (7.5) 4 (16.0)
 Asian 2 (9.1) 1 (2.5) 0 (0)
 Hispanic 1 (4.5) 1 (2.5) 2 (8.0)
AJCC stage at diagnosisa, number (%)    
 Stage 1 14 (63.6) 0 (0) 6 (24.0)
 Stage 2 6 (27.3) 21 (52.5) 15 (60.0)
 Stage 3 2 (9.1) 19 (47.5) 4 (16.0)
Hormone receptor status, number (%)    
 ER/PRpos 12 (54.5) 18 (45.0) 11 (44.0)
 ER/PRneg 10 (45.5) 22 (55.0) 14 (56.0)
Time from completion of trastuzumab to study enrollment, number (%)    
 <6 months   18 (45.0) 10 (40.0)
 ≥6 months   22 (55.0) 15 (60.0)
  1. aFor neoadjuvant cohort, AJCC clinical stage is shown. HER2 pos Human epidermal growth factor receptor overexpressing, IBC invasive breast cancer, T + C trastuzumab and chemotherapy, AJCC American Joint Committee on Cancer, ER estrogen receptor, PR progesterone receptor